| Pharmaceutical Information |
| Drug Name |
Aldesleukin |
| Drug ID |
BADD_D00062 |
| Description |
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. |
| Indications and Usage |
For treatment of adults with metastatic renal cell carcinoma. |
| Marketing Status |
Prescription |
| ATC Code |
L03AC01 |
| DrugBank ID |
DB00041
|
| KEGG ID |
D00748
|
| MeSH ID |
C082598
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D05PUD
|
| NDC Product Code |
17089-380; 76310-022 |
| Synonyms |
aldesleukin | Proleukin | BAY 50-4798 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
110942-02-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
